{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-067043","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.819866+00:00","generated_at":"2026-05-22T05:16:06.843293+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Revelation Biosciences Q1 net loss $2.1M; cash only to June 2025","bullets":["Cash and equivalents $3.7M at March 31, 2025, down from $6.5M at Dec 31, 2024.","Net loss $2.1M ($2.11 per share) vs $2.7M ($39.37 per share) in Q1 2024.","Operating cash burn $2.8M in Q1 2025, same as Q1 2024.","Management says current cash sufficient only through June 2025.","New indication for Gemini in severe burns; topline PRIME Phase 1b data expected summer 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-067043","json":"https://secwatch.observer/filing/0000950170-25-067043.json","markdown":"https://secwatch.observer/filing/0000950170-25-067043.md","text":"https://secwatch.observer/filing/0000950170-25-067043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000095017025067043/0000950170-25-067043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000095017025067043/revb-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T05:16:06.843293+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}